Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHAPAS-5 HIV treatment options trial for children and adolescents in Africa
ISRCTN17340368Phase 3Not yet recruiting
- Sponsor
- University College London
- Start
- Nov 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of dolutegravir, abacavir, lamivudine, tenofovir alafenamide, emtricitabine and 3 more in human immunodeficiency virus infection (HIV) (6 arms), sponsored by University College London. Primary endpoint: Primary: HIV viral suppression at week 48. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
dolutegravirabacavirlamivudinetenofovir alafenamideemtricitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ISRCTN17340368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17340368.